Home MarketSuven Life Sciences Ltd.

Suven Life Sciences Ltd. Stock Info: As on 2018-05-24 15:56:56

Nse

189.90

-2.25(-1.17%)
Change%
52 Week Range
155.00
11.00
250.80
29.00
Open192.75
Day's Range153.72 - 230.58
Value Traded (in ₹ Cr.) 4.50

Bse

189.90

-1.95(-1.02%)
Change %
52 Week Range
155.00
11.00
250.80
29.00
Open193.85
Day's Range153.48 - 230.22
Value Traded (in ₹ Cr.) 0.88

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 76,370,000.00 60.00%
Mutual Funds/UTI 5,651,388.00 4.44%
FII 3,182,470.00 2.50%
Employee 0.00 0.00%
Public 30,770,171.00 24.17%
Government 0.00 0.00%
Others 10,792,774.00 8.48%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 3.88
Basic EPS (Rs.) 9.69
Cash EPS 11.38
BVPerShare Excl 57.47
Operating Revenue 42.70
PBDITPerShare 14.65
Dividend 1.00
NPPerShare 9.70
Current Ratio 4.25
Quick Ratio 3.45
PriceToBV 2.88
Earnings 0.05
PBDIT Margin 34.30
PBT Margin 29.31
NP Margin 22.71
Return On Assets 14.09
Retention Ratios 89.69
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 564.62
Total Expenses 405.27
EBITDA 186.44
PBT 159.36
PAT 123.47
Net Income 123.47
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 389.90
Total Expenses 245.52
EBITDA 133.59
PBT 141.97
PAT 97.11
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 12.73
Net worth 731.53
Investments 365.97
Total Liability 876.17
Total debt 56.42
Net block 315.44
Total Assets 876.17
Parameter Sep-17 (₹ Cr.) 6M % change
Total share capital 12.73
Net worth 604.27
Investments 237.23
Total Liability 812.49
Total debt 93.72
Net block 303.53
Total Assets 812.49
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 146.94
Cash from investing activities -352.64
Cash from financing activities -30.00
Net change in cash -235.71

Stock Held By Mutual Fund Schemes

Corporate Details

About Management

Brief History and business of the Company Suven Pharmaceuticals Limited was promoted in 1989 by Mr.Jasti Venkateswarlu and Mrs. Jasti Sudha Rani for the manufacture of bulk drugs and drug intermediates. The Company was incorporated as a Private Limited Company on 9th March, 1989 in the state of Andhra Pradesh. Subsequently on 4th January, 1995 it was converted into a Public Limited Company in terms of special resolution dated 25.11.94 U/s. 31(1)/44 of Companies Act. - The Company deveops and manufactures drug intermediates, under contract from the drug's global patent holders. 2000 - The Company has entered into agreement with NSDL and CDSL for dematerialisation of shares. - Company bags export orders of Rs 21 cr 2001 - Borregaard Industries Ltd, Norway, acquires 15% stake in the company 2002- An accident occurred at the company's Suryapet Unit AS when a transporters vehicle entered the factory premises on November 17, 2002 -Pfizer Ltd and Suven Pharmaceuticals Ltd have tied up with the Bombay College of Pharmacy to set up an academy for clinical excellence (ACE) , in Mumbai. 2003-Borregaard Industries Ltd, a Norwegean pharma player has offloaded its entire 17.05 per cent stake ( 7.50 lakh equity shares) in Suven Life Sciences Ltd -Suven Life Sciences USA LLC a wholly owned subsidiary of Suven Pharmaceuticals Ltd has acquired Synthon Chiragenics Corporation New Jersey USA 2004 -Suven Life Sciences Ltd has informed the stock exchanges that its shareholders at the extraordinary general meeting held on Jan 05 have approved the sub-division of equity shares into face value of Rs 2 each from the face value of Rs 10 each. -Suven Life Sciences BoD approves preferential shares issue -Suven Life Sciences Ltd has said that its board of directors on Jan 19 has allotted 30 lakh equity shares of face value of Rs 2 each on preferential basis to four investors. While Emerging Markets Management LLC was allotted 10 lakh shares, Aeneas Portfolio Company LP 8.75 lakh shares, Commonwealth Equity Fund Ltd, a sub-account of Batterymarch Financial Management Inc, 6.25 lakh shares and Mr Rambabu Chirumamilla was given 5 lakh shares. -Two units of Suven Life (Suryapet & Jeedimetla) get ISO confirmation 2007 - Suven Life Sciences Ltd (Suven) on November 27, 2007 has announced that the European Patent Office (EPO) granted Two Patents, 1523486 and 1581538 to Suven and are valid until June 2022. -The Company has issued Bonus Shares in the Ratio of 1:1. - The Company has splits its face value from Rs2/- to Rs1/-. 2009 - Suven Life Sciences has secured two U.S. patents relating to new chemical entities (NCEs) for treatment of disorders associated with neurodegenerative diseases - Suven Life Sciences Ltd (Suven) announces today that the European Patent Office (EPO) has Issued 3 new Patents: EP1537113, EP1704154 and EP1856132 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2022,23 and 24 respectively. 2010 -Suven Secures Two product patents in China and Russia -Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System -Suven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders. -Suven Life Secures Three Australian Patents on NCEs -Suven gets two patents from Japanese Patent Office for NCE's 2011 -Suven's Unit-III receives US FDA Acceptance -Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world -Suven Life Sciences bags "Bio-Excellence Award at Bangalore India Bio 2011 -Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world -Suven Life Sciences bags Pharmexcil's Gold "Patent Award" 2012 -Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA -Suven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and Eurasia -Suven Life Sciences bags Pharmexcil's "Platinum Patent Award" -Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea. 2013 - Suven Life Sciences bags 4 Product Patents for their NCEs in China, Mexico and New Zealand" - Suven Life secures three Product Patents for their NCEs in Canada and Eurasia" - Suven Life secures two (2) Product Patents for their NCEs in Europe - The Company has recommended Dividend Re. 30 paisa per equity share of face value of Re. 1/-. 2014 - SUVEN'S PASHAMYLARAM'S UNIT RECEIVES US FDA ACCEPTANCE - Suven Life Sciences bags Pharmexcil's 'Gold Patent Award' for NCE's and 'Outstanding Export Performance Award' for Contract Research and Manufacturing. - Suven Life Sciences awarded Forbes Asia's "Best Under A Billion" Award 2015 - Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical Trial for their investigational compound SUVN-G3031 - Suven Life Sciences bags Pharmexcil's Gold Patent Award

Registered Office

Unit - 4: Plot No(s). 65 - 67, JN Pharmacity, Parwada

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.